Dynavax Technologies Corporation
$ 15.50
0.00%
11 Feb - close price
- Market Cap 1,820,087,000 USD
- Current Price $ 15.50
- High / Low $ 15.50 / 15.50
- Stock P/E N/A
- Book Value 4.55
- EPS -0.37
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.07 %
- 52 Week High 15.73
- 52 Week Low 9.20
About
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.
Analyst Target Price
$16.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-02-20 | 2024-11-07 | 2024-08-06 | 2024-05-08 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-02 |
| Reported EPS | 0 | 0.21 | 0.14 | -0.0091 | 0.05 | 0.12 | 0.08 | -0.07 | 0.0016 | 0.1 | 0.03 | -0.19 |
| Estimated EPS | 0.0367 | 0.13 | 0.1 | 0.0123 | 0.04 | 0.11 | 0.06 | -0.02 | -0.01 | -0.01 | -0.09 | -0.13 |
| Surprise | -0.0367 | 0.08 | 0.04 | -0.0214 | 0.01 | 0.01 | 0.02 | -0.05 | 0.0116 | 0.11 | 0.12 | -0.06 |
| Surprise Percentage | -100% | 61.5385% | 40% | -173.9837% | 25% | 9.0909% | 33.3333% | -250% | 116% | 1100% | 133.3333% | -46.1538% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.0767 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DVAX
2026-02-16 10:27:23
Principal Financial Group Inc. reduced its stake in Dynavax Technologies Corporation by 12.9% in the third quarter, selling over 70,000 shares. This comes amidst insider selling by COO David F. Novack, who decreased his holding by over 64%. Despite institutional ownership at nearly 97%, the biopharmaceutical company holds a consensus "Hold" rating from Wall Street with a target price of $24.33, while currently trading at $15.50 with a negative PE ratio.
2026-02-14 22:27:23
Wall Street Zen has upgraded Dynavax Technologies (NASDAQ:DVAX) to a "strong-buy" rating, despite other analysts generally maintaining a "Hold" consensus with a $24.33 price target. The article notes recent insider selling by COO David F. Novack, who sold a significant portion of his holdings, while institutional ownership remains high. Dynavax, a biopharmaceutical company known for its HEPLISAV-B vaccine, has shown strong liquidity metrics and a market capitalization of $1.82 billion.
2026-02-12 19:27:25
Sanofi has finalized its $2.2 billion acquisition of Dynavax Technologies, a vaccines company. The acquisition brings Dynavax's adult hepatitis B vaccine, Heplisav-B, known for its two-dose regimen, into Sanofi's portfolio, along with a shingles vaccine candidate and other pipeline projects. This move strengthens Sanofi's position in the vaccine market.
2026-02-10 21:57:58
Dynavax Technologies Corporation (DVAX) announced that it requested Nasdaq to halt trading and delist its shares effective February 10, 2026, following the closing of its merger. The company also plans to file forms to remove its shares from listing and registration and to terminate its reporting obligations under the Exchange Act. This action was taken after consummating the merger.
2026-02-10 14:28:39
Dynavax Technologies (DVAX) has signed two First Supplemental Indentures with U.S. Bank Trust Company, amending its 2.50% Convertible Senior Notes due 2026 and 2.00% Convertible Senior Notes due 2030. These amendments, effective February 10, 2026, convert the settlement mechanism to cash-only based on a $15.50 offer price following a merger. This change reflects the merger being considered a fundamental change and make-whole event as per the indentures.
2026-02-10 14:28:39
Dynavax Technologies Corp (DVAX) announced significant board and executive team changes on February 10, 2026, following a merger. François-Xavier Dazogbo has been appointed as the sole director and officer, with several other individuals stepping into key executive roles. The changes include both resignations and appointments, effective immediately after the merger.
